Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.
- The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.
- The Company has updated its corporate presentation to reflect these business and strategic updates.
- Additionally, the Immunocore management team will discuss these updates during a live and webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference, on Wednesday January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST).
- The presentation and webcast will be available in the ‘Investors/Media’ section of Immunocore’s website at www.immunocore.com.